BioPharma Dive June 14, 2024
BioPharma Dive staff

The Japanese pharma paid $100 million to secure option rights to a third-generation TKI inhibitor, while a venture arm of the big investment bank closed its inaugural life sciences fund.

Today, a brief rundown of news from Takeda and the Food and Drug Administration, as well as updates from Insmed, J.P. Morgan and Bristol Myers Squibb that you may have missed from earlier this week.

Takeda Pharmaceutical has paid $100 million for an exclusive option to license a blood cancer medicine from China-based Ascentage Pharma. Known as olverembatinib, the medicine is already approved and marketed in China for certain adult patients with chronic myeloid leukemia. It blocks members of the “tyrosine kinase” enzyme family that are integral to the onset...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others
Weight Loss Drugs’ Effects Could Be Improved by Priming Melanocortin System
J&J IRA pricing offer is in, as it sticks with 2025 guidance

Share This Article